Chronic inflammatory demyelinating polyneuropathy
Other Names for this Disease
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
The standard therapies for CIDP appear to be equally effective and include:
- intravenous immune globulin (IVIG) - adds large numbers of antibodies to the blood plasma to reduce the effect of the antibodies that are causing the problem
- glucocorticoids - help reduce inflammation and relieve symptoms
- plasma exchange - remove antibodies from the blood
- IVIG and plasma exchange may lead to a more rapid improvement in CIDP than glucocorticoid therapy, but are less likely than glucocorticoids to produce a remission
- IVIG is expensive, and its supply is sometimes limited
- Glucocorticoids are inexpensive, but chronic use is limited by common and important side effects
- Plasma exchange is expensive, invasive, and available only at specialized centers
Last updated: 11/23/2015
- Richard A Lewis. Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis. UpToDate. Waltham, MA: UpToDate; October, 2015;
- Chronic inflammatory polyneuropathy. MedlinePlus. July 27, 2014; https://www.nlm.nih.gov/medlineplus/ency/article/000777.htm.
- NINDS Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Information Page. NINDS. November 6, 2015; http://www.ninds.nih.gov/disorders/cidp/cidp.htm.
- Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.
- ClinicalTrials.gov lists trials that are studying or have studied Chronic inflammatory demyelinating polyneuropathy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
|Generic Name||Immune Globulin (Human)|
The FDA has approved this product to be used in this manner.
|Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information